 Immunoglobulin Light Chains
"Immunoglobulin Light Chains" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Polypeptide chains, consisting of 211 to 217 amino acid residues and having a molecular weight of approximately 22 kDa. There are two major types of light chains, kappa and lambda. Two Ig light chains and two Ig heavy chains (IMMUNOGLOBULIN HEAVY CHAINS) make one immunoglobulin molecule.
| Descriptor ID |
D007147
|
| MeSH Number(s) |
D12.776.124.486.485.705.750 D12.776.124.790.651.705.750 D12.776.377.715.548.705.750
|
| Concept/Terms |
Immunoglobulin Light Chains- Immunoglobulin Light Chains
- Chains, Immunoglobulin Light
- Light Chains, Immunoglobulin
- Immunoglobulin Light-Chain
- Light-Chain, Immunoglobulin
- Light-Chain Immunoglobulins
- Light Chain Immunoglobulins
- Immunoglobulin Light Chain
- Light Chain, Immunoglobulin
- Immunoglobulins, Light-Chain
- Immunoglobulins, Light Chain
|
Below are MeSH descriptors whose meaning is more general than "Immunoglobulin Light Chains".
Below are MeSH descriptors whose meaning is more specific than "Immunoglobulin Light Chains".
This graph shows the total number of publications written about "Immunoglobulin Light Chains" by people in UAMS Profiles by year, and whether "Immunoglobulin Light Chains" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 1 | 2 | | 2023 | 1 | 2 | 3 | | 2022 | 1 | 1 | 2 | | 2021 | 2 | 2 | 4 | | 2020 | 2 | 2 | 4 | | 2019 | 1 | 0 | 1 | | 2018 | 2 | 1 | 3 | | 2017 | 1 | 1 | 2 | | 2016 | 3 | 0 | 3 | | 2015 | 2 | 0 | 2 | | 2014 | 4 | 1 | 5 | | 2013 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2010 | 1 | 0 | 1 | | 2009 | 0 | 1 | 1 | | 2008 | 1 | 0 | 1 | | 2007 | 2 | 1 | 3 | | 2005 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 1995 | 1 | 1 | 2 | | 1994 | 0 | 2 | 2 | | 1990 | 0 | 1 | 1 | | 1989 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Immunoglobulin Light Chains" by people in Profiles over the past ten years.
-
Giles HV, Drayson MT, Kishore B, Pawlyn C, Kaiser M, Cook G, de Tute R, Owen RG, Cairns D, Menzies T, Davies FE, Morgan GJ, Pratt G, Jackson GH. Progression free survival of myeloma patients who become IFE-negative correlates with the detection of residual monoclonal free light chain (FLC) by mass spectrometry. Blood Cancer J. 2024 Mar 18; 14(1):50.
-
Wong S, West ME, Morgan GJ. Kinetic evidence for multiple aggregation pathways in antibody light chain variable domains. Protein Sci. 2024 Mar; 33(3):e4871.
-
Chakraborty R, Bhutani D, Maurer MS, Mohan M, Lentzsch S, D'Souza A. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis. Blood Cancer J. 2023 11 27; 13(1):172.
-
Yan NL, Morgan GJ, Petrassi HM, Wilson IA, Kelly JW. Pharmacological stabilization of the native state of full-length immunoglobulin light chains to treat light chain amyloidosis. Curr Opin Chem Biol. 2023 08; 75:102319.
-
Nau A, Shen Y, Sanchorawala V, Prokaeva T, Morgan GJ. Complete variable domain sequences of monoclonal antibody light chains identified from untargeted RNA sequencing data. Front Immunol. 2023; 14:1167235.
-
Steinhardt M, Kort?m M, Einsele H, Rasche L. [Monoclonal gammopathy of (un)known significance]. Dtsch Med Wochenschr. 2022 06; 147(11):675-682.
-
Yan NL, Nair R, Chu A, Wilson IA, Johnson KA, Morgan GJ, Kelly JW. Amyloidogenic immunoglobulin light chain kinetic stabilizers comprising a simple urea linker module reveal a novel binding sub-site. Bioorg Med Chem Lett. 2022 03 15; 60:128571.
-
Foureau D, Bhutani M, Guo F, Rigby K, Leonidas M, Tjaden E, Fox A, Atrash S, Paul B, Voorhees PM, Usmani SZ. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma. Cancer Med. 2021 10; 10(20):6933-6936.
-
Morgan GJ. Barriers to Small Molecule Drug Discovery for Systemic Amyloidosis. Molecules. 2021 Jun 11; 26(12).
-
Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021 02 01; 11(2):24.
-
Chyra Z, Sevcikova T, Vojta P, Puterova J, Brozova L, Growkova K, Filipova J, Zatopkova M, Grosicki S, Barchnicka A, Jedrzejczak WW, Waszczuk-Gajda A, Jungova A, Mikulasova A, Hajduch M, Mokrejs M, Pour L, Stork M, Harvanova L, Mistrik M, Mikala G, Robak P, Czyz A, Debski J, Usnarska-Zubkiewicz L, Jurczyszyn A, Stejskal L, Morgan G, Kryukov F, Budinska E, Simicek M, Jelinek T, Hrdinka M, Hajek R. Heterogenous mutation spectrum and deregulated cellular pathways in aberrant plasma cells underline molecular pathology of light-chain amyloidosis. Haematologica. 2021 02 01; 106(2):601-604.
-
Rana R, Cockwell P, Drayson M, Cook M, Pratt G, Cairns DA, Pawlyn C, Jackson G, Davies F, Morgan G, Pinney JH. Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial. Blood Adv. 2020 11 24; 4(22):5836-5845.
-
Shen KN, Miao HL, Zhang CL, Feng J, Zhang L, Cao XX, Zhou DB, Wei S, Li J. Posttreatment dFLC less than 10?mg/L predicts superior organ response and longer time to next treatment in newly diagnosed light-chain amyloidosis patients treated with bortezomib. Leuk Lymphoma. 2021 04; 62(4):874-882.
-
Mateos MV, Kumar S, Dimopoulos MA, Gonz?lez-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020 10 16; 10(10):102.
-
Morgan GJ, Wall JS. The Process of Amyloid Formation due to Monoclonal Immunoglobulins. Hematol Oncol Clin North Am. 2020 12; 34(6):1041-1054.
-
Heaney JLJ, Richter A, Bowcock S, Pratt G, Child JA, Jackson G, Morgan G, Turesson I, Drayson MT. Excluding myeloma diagnosis using revised thresholds for serum free light chain ratios and M-protein levels. Haematologica. 2020 04; 105(4):e169-e171.
-
Rennella E, Morgan GJ, Kelly JW, Kay LE. Role of domain interactions in the aggregation of full-length immunoglobulin light chains. Proc Natl Acad Sci U S A. 2019 01 15; 116(3):854-863.
-
Wu X, Zhang L, Feng J, Mao YY, Cao XX, Zhou DB, Li J. Bortezomib-based chemotherapy can improve renal and tubular functions in patients with light chain-associated Fanconi syndrome. Ann Hematol. 2019 May; 98(5):1095-1100.
-
Yadav P, Cockwell P, Cook M, Pinney J, Giles H, Aung YS, Cairns D, Owen RG, Davies FE, Jackson GH, Child JA, Morgan GJ, Drayson MT. Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma. BMC Nephrol. 2018 07 13; 19(1):178.
-
Mohan M, Buros A, Mathur P, Gokden N, Singh M, Susanibar S, Jo Kamimoto J, Hoque S, Radhakrishnan M, Matin A, Davis C, Grazziutti M, Thanendrarajan S, van Rhee F, Zangari M, Davies F, Morgan G, Epstein J, Barlogie B, Schinke C. Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease. Am J Hematol. 2017 Aug; 92(8):739-745.
-
Heaney JLJ, Campbell JP, Griffin AE, Birtwistle J, Shemar M, Child JA, Gregory WM, Cairns DA, Morgan G, Jackson G, Drayson MT. Diagnosis and monitoring for light chain only and oligosecretory myeloma using serum free light chain tests. Br J Haematol. 2017 07; 178(2):220-230.
-
Morgan GJ, Kelly JW. The Kinetic Stability of a Full-Length Antibody Light Chain Dimer Determines whether Endoproteolysis Can Release Amyloidogenic Variable Domains. J Mol Biol. 2016 10 23; 428(21):4280-4297.
-
Abbi KK, Silverman M, Farooq U, Tricot A, Dozeman L, Nadiminti K, Krasowski MD, Tricot GJ. Potential pitfalls of serum free light chain analysis to assess treatment response for multiple myeloma. Br J Haematol. 2016 08; 174(4):536-40.
-
Mohan M, Gokden M, Gokden N, Schinke C. A Case of Cardiac Light Chain Deposition Disease in a Patient with Solitary Plasmacytoma. Am J Case Rep. 2016 Mar 18; 17:173-6.
-
Wang C, Su W, Cai QQ, Cai H, Ji W, Di Q, Duan MH, Cao XX, Zhou DB, Li J. Prognostic value of serum heavy/light chain ratios in patients with POEMS syndrome. Eur J Haematol. 2016 Jul; 97(1):48-54.
-
Papanikolaou X, Alapat D, Rosenthal A, Stein C, Epstein J, Owens R, Yaccoby S, Johnson S, Bailey C, Heuck C, Tian E, Joiner A, van Rhee F, Khan R, Zangari M, Jethava Y, Waheed S, Davies F, Morgan G, Barlogie B. The flow cytometry-defined light chain cytoplasmic immunoglobulin index and an associated 12-gene expression signature are independent prognostic factors in multiple myeloma. Leukemia. 2015 Aug; 29(8):1713-20.
-
Cooley CB, Ryno LM, Plate L, Morgan GJ, Hulleman JD, Kelly JW, Wiseman RL. Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain. Proc Natl Acad Sci U S A. 2014 Sep 09; 111(36):13046-51.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|